P4‐239: The role of elisa in early diagnosis of Alzheimer's disease

The aim of our study was to establish the relationship with cognitive performance level of DHEA-S with early form of Alzheimer's disease (AD). The study included 30 patients (12 men and 18 women), aged 65 (average age 61,3 ± 5,7 years) years from the presence of cognitive impairment, and 5 healthy individuals. Research was conducted by ELISA with the definition of the level of DHEA-S before and after the oxidation catalyst Fe2+. Clinic of AD in patients of the main group was characterized by the presence of organic neurological deficits and a progressive decline in cognitive function. Neuropsychological research on the MMSE results suggests cognitive functions: 21,8 ± 4,05 in the group of patients with asthma, 28,1 ± 0,8 in healthy individuals. Oxidation of serum led to a sharp increase in DHEA levels in the control group (up to 5,2 ± 0,5; after 7,1 ± 0,5), whereas in the serum of patients with AD, improving wasn't observed or was negligible (up to 2,1 ± 0,5; after 2,3 ± 0,3). Determining the level of DHEA and the reaction of Fe2+ may be taken as one of the biochemical markers of diagnosis of early forms of AD, which can be recommended for screening diagnosis of early forms of AD.

Ҳали таржима қилинмаган